Abstract:Purpose: This study aimed to retrospectively compare the efficacy and safety of micro-radiofrequency (RF) therapy through the urethra vs. oral tolterodine tartrate in the treatment of newly diagnosed overactive bladder (OAB). Materials and methods: In this study, 46 patients who were newly diagnosed with moderate-to-severe OAB were included; 23 of them underwent the micro-RF treatment procedure, and the other 23 patients took tolterodine. Bladder diaries were recorded 3 days before treatment and during the follow-up period on 1, 3, and 7 weeks after micro-RF therapy or oral tolterodine. Micturition parameters including daily voiding times, daily urge urinary incontinence (UI) episodes, daily urgency episodes, mean volume per micturition, post-void residual volume (PVR), maximum urine flow rate (Qmax), overactive bladder symptom score (OABSS), and quality of life (QoL) score were analyzed. Results: All 46 patients underwent either micro-RF or oral tolterodine treatment, as well as a complete follow-up. The incidence of adverse events in the micro-RF group was 8.7% (2/23), and that in the tolterodine group was 43.5% (10/23). The following two adverse events happened in the micro-RF group: an injury to the urethra during catheterization in a man and a urinary tract infection in a woman, both of which were relieved or disappeared after day 3. The adverse effects in the tolterodine group were mainly dry mouth (4/23), dysuria (5/23), and constipation (8/23), but none of the patients withdrew from the drug therapy. Compared to pre-therapy, all parameters of both groups, including daily voiding times, daily urgency episodes, mean volume per micturition, OABSS, and QoL score, demonstrated significant improvements during follow-up in 7 weeks after therapy, except for daily UI episodes in the tolterodine group, while the above parameters showed bigger improvements in the micro-RF group than in the tolterodine group. Besides, the general treatment efficacy of micro-RF was 73.9% (17/23), which was significantly better than tolterodine (10/23, 43.5%), and the difference was 30.4% [95% CI: 3.4-57.5%, p = 0.036]. Conclusion: In this retrospective study, we found that micro-RF therapy is safe and more effective than oral tolterodine for newly diagnosed moderate-to-severe OAB in a short-term follow-up. Stronger evidence would be provided through a well-designed, prospective, randomized controlled trial.

Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study

The Effect of Pelvic Floor Magnetic Stimulation in Women with Myofascial Pelvic Pain Syndrome: A Prospective Cohort Pilot Study

Efficacy of the combination of transcutaneous tibial nerve stimulation and mirabegron in women with overactive bladder in a prospective randomized controlled trial

Efficacy And Safety Of Combinations Of Mirabegron And Solifenacin In Patients With Overactive Bladder: A Systematic Review And Meta-Analysis

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study

Biofeedback-Assisted pelvic floor muscle training combined with a short-duration drug regimen is safe and effective in women with overactive bladder: A randomized controlled trial

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis

Results of a Randomized, Double‐blind, Parallel‐group, Placebo‐ and Active‐controlled, Multicenter Study of Mirabegron, a Β3‐adrenoceptor Agonist, in Patients with Overactive Bladder in Asia

A Single-Centre Randomized Sham-Controlled Study

Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials

Efficacy and Safety of Mirabegron in the Treatment of Overactive Bladder Syndrome after Radical Prostatectomy: a Prospective Randomized Controlled Study

The Efficacy and Safety of Mirabegron for Adult and Child Patients with Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-Analysis

Disease Correlation and Effects of Pelvic Floor Muscle Training on Tolterodine Based Treatment for Female Primary Overactive Bladder Syndrome

[Magnetic stimulation combined with moxibustion improves mild to moderate overactive bladder and sexual function in women]

Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study

Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study

The Effects of Pelvic Floor Muscle Training on Symptom and Quality of Life in Female Patients with Overactive Bladder

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

Clinical application of mirabegron in the treatment of overactive bladder

Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome—A Systematic Review

Open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder